JP2014530012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530012A5 JP2014530012A5 JP2014533413A JP2014533413A JP2014530012A5 JP 2014530012 A5 JP2014530012 A5 JP 2014530012A5 JP 2014533413 A JP2014533413 A JP 2014533413A JP 2014533413 A JP2014533413 A JP 2014533413A JP 2014530012 A5 JP2014530012 A5 JP 2014530012A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pge
- cell
- stem cells
- retrovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 53
- 210000004027 cell Anatomy 0.000 claims description 35
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 32
- 210000000130 stem cell Anatomy 0.000 claims description 30
- 241001430294 unidentified retrovirus Species 0.000 claims description 25
- 102000008866 Prostaglandin E receptors Human genes 0.000 claims description 23
- 108010088540 Prostaglandin E receptors Proteins 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 150000003180 prostaglandins Chemical class 0.000 claims description 21
- 230000011664 signaling Effects 0.000 claims description 21
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 12
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 12
- 230000026683 transduction Effects 0.000 claims description 10
- 238000010361 transduction Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000001177 retroviral effect Effects 0.000 claims description 5
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims description 4
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 4
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 229930189037 Trapoxin Natural products 0.000 claims description 4
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims description 4
- 210000004165 myocardium Anatomy 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 210000002027 skeletal muscle Anatomy 0.000 claims description 4
- 108010060597 trapoxin A Proteins 0.000 claims description 4
- 108700001624 vesicular stomatitis virus G Proteins 0.000 claims description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000237 vorinostat Drugs 0.000 claims description 4
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 3
- 101000760602 Homo sapiens ATP-binding cassette sub-family D member 1 Proteins 0.000 claims description 3
- 108091027981 Response element Proteins 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 102000047168 human ABCD1 Human genes 0.000 claims description 3
- 239000012212 insulator Substances 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- 229960000604 valproic acid Drugs 0.000 claims description 3
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 claims description 2
- LLVVDFDWPQHXBA-QEJIITRLSA-N 11-Deoxy-16,16-dimethyl-PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O LLVVDFDWPQHXBA-QEJIITRLSA-N 0.000 claims description 2
- TUXFWOHFPFBNEJ-GJGHEGAFSA-N 13,14-dihydro-Delta(12)-prostaglandin J2 Chemical compound CCCCC[C@H](O)C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O TUXFWOHFPFBNEJ-GJGHEGAFSA-N 0.000 claims description 2
- XSGQFHNPNWBVPT-DSFPJDRCSA-N 15-Methyl-15S-PGE2 Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-DSFPJDRCSA-N 0.000 claims description 2
- XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 claims description 2
- DXWJXQSQVUJRNS-YYWARMNLSA-N 16-Phenyl-tetranor-PGE2 Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)C1=CC=CC=C1 DXWJXQSQVUJRNS-YYWARMNLSA-N 0.000 claims description 2
- XTNOEYFQXCQKLC-UHFFFAOYSA-N 18-(oxiren-2-yl)octadeca-15,17-dienoic acid Chemical compound C1=C(C=CC=CCCCCCCCCCCCCCC(=O)O)O1 XTNOEYFQXCQKLC-UHFFFAOYSA-N 0.000 claims description 2
- WTJYDBMHYPQFNJ-ZUVVJKHESA-N 19R-Hydroxy-PGE2 Chemical compound C[C@@H](O)CCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O WTJYDBMHYPQFNJ-ZUVVJKHESA-N 0.000 claims description 2
- RKHRWGLENCONFM-UHFFFAOYSA-N 2-hydroxyheptadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC=CC=CC=C(O)C(O)=O RKHRWGLENCONFM-UHFFFAOYSA-N 0.000 claims description 2
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims description 2
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 claims description 2
- VKEJXDXJUFQESA-DLMPNJEASA-N 9-Deoxy-9-methylene-PGE2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O VKEJXDXJUFQESA-DLMPNJEASA-N 0.000 claims description 2
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 claims description 2
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- 102400000967 Bradykinin Human genes 0.000 claims description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 2
- 108010002156 Depsipeptides Proteins 0.000 claims description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims description 2
- 101710091045 Envelope protein Proteins 0.000 claims description 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930188389 Lanatoside Natural products 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims description 2
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 2
- 101710188315 Protein X Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- YFGQJKBUXPKSAW-ZUDKKNPISA-N [(2r,3r,4s)-6-[(2r,3s,4s)-4-hydroxy-6-[(2r,3s,4s)-4-hydroxy-6-[[(3s,9s,10s,13r,17r)-14-hydroxy-10,13-dimethyl-17-(5-oxo-2h-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxan-3-yl]oxy-2-methyloxan-3-y Chemical compound O([C@H]1[C@@H](OC(C)=O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@H]1[C@@H](O)CC(O[C@@H]1C)O[C@@H]1CC2[C@]([C@@H]3C(C4(CC[C@@H]([C@@]4(C)CC3)C=3COC(=O)C=3)O)CC2)(C)CC1)C1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1O YFGQJKBUXPKSAW-ZUDKKNPISA-N 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000003651 basophil Anatomy 0.000 claims description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- 229950008654 butaprost Drugs 0.000 claims description 2
- UMMADZJLZAPZAW-OVXHCKHTSA-N carboprost tromethamine Chemical compound OCC([NH3+])(CO)CO.CCCCC[C@](C)(O)\C=C\[C@H]1[C@@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC([O-])=O UMMADZJLZAPZAW-OVXHCKHTSA-N 0.000 claims description 2
- 229960005296 carboprost tromethamine Drugs 0.000 claims description 2
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 claims description 2
- 229960001761 chlorpropamide Drugs 0.000 claims description 2
- 210000001612 chondrocyte Anatomy 0.000 claims description 2
- 230000002648 chondrogenic effect Effects 0.000 claims description 2
- 229960004409 cloprostenol Drugs 0.000 claims description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 2
- 108010027178 cyclic hydroxamic acid-containing peptide 1 Proteins 0.000 claims description 2
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 2
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 229960004979 fampridine Drugs 0.000 claims description 2
- 229960002602 fendiline Drugs 0.000 claims description 2
- 229950004346 gaboxadol Drugs 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 210000003897 hepatic stem cell Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 229960002474 hydralazine Drugs 0.000 claims description 2
- 229960002240 iloprost Drugs 0.000 claims description 2
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 claims description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004801 imipramine Drugs 0.000 claims description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 229940124280 l-arginine Drugs 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000003593 megakaryocyte Anatomy 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 2
- XRISENIKJUKIHD-LHQZMKCDSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,4r)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCC1([C@H](O)C\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCCCCCC(=O)OC)CCC1 XRISENIKJUKIHD-LHQZMKCDSA-N 0.000 claims description 2
- 150000004702 methyl esters Chemical class 0.000 claims description 2
- 229960005249 misoprostol Drugs 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000000963 osteoblast Anatomy 0.000 claims description 2
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 2
- 229960005184 panobinostat Drugs 0.000 claims description 2
- 229960005152 pentetrazol Drugs 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 229930182884 serinolamide Natural products 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 2
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 2
- 229960002232 sodium phenylbutyrate Drugs 0.000 claims description 2
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 claims description 2
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 claims description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 2
- 229960003400 sulprostone Drugs 0.000 claims description 2
- UQZVCDCIMBLVNR-TWYODKAFSA-N sulprostone Chemical compound O[C@@H]1CC(=O)[C@H](C\C=C/CCCC(=O)NS(=O)(=O)C)[C@H]1\C=C\[C@@H](O)COC1=CC=CC=C1 UQZVCDCIMBLVNR-TWYODKAFSA-N 0.000 claims description 2
- 229960004458 tafluprost Drugs 0.000 claims description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 claims description 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004546 thiabendazole Drugs 0.000 claims description 2
- 235000010296 thiabendazole Nutrition 0.000 claims description 2
- 239000004308 thiabendazole Substances 0.000 claims description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims description 2
- 210000005167 vascular cell Anatomy 0.000 claims description 2
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 229960002508 pindolol Drugs 0.000 claims 1
- BVTYOCKAKQQPEE-UHFFFAOYSA-N superphane Chemical compound C1=2CCC3=C4CCC=2C(=C2CC5)CCC4=C5C4=C3CCC1=C2CC4 BVTYOCKAKQQPEE-UHFFFAOYSA-N 0.000 claims 1
- MOILFCKRQFQVFS-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1C2C(C)(C)C1CC(O)C2(O)C MOILFCKRQFQVFS-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- -1 phenyl ester Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 229960005032 treprostinil Drugs 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541736P | 2011-09-30 | 2011-09-30 | |
| US61/541,736 | 2011-09-30 | ||
| PCT/US2012/057987 WO2013049615A1 (en) | 2011-09-30 | 2012-09-28 | Compounds for improved viral transduction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017184A Division JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530012A JP2014530012A (ja) | 2014-11-17 |
| JP2014530012A5 true JP2014530012A5 (enExample) | 2015-11-12 |
| JP6285863B2 JP6285863B2 (ja) | 2018-02-28 |
Family
ID=47996444
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533413A Active JP6285863B2 (ja) | 2011-09-30 | 2012-09-28 | 改善されたウイルスによる形質導入のための化合物 |
| JP2018017184A Expired - Fee Related JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017184A Expired - Fee Related JP6745826B2 (ja) | 2011-09-30 | 2018-02-02 | 改善されたウイルスによる形質導入のための化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9988644B2 (enExample) |
| EP (4) | EP4095236A1 (enExample) |
| JP (2) | JP6285863B2 (enExample) |
| KR (1) | KR102011532B1 (enExample) |
| CN (2) | CN103958667A (enExample) |
| AU (1) | AU2012315699B2 (enExample) |
| BR (1) | BR112014007782B1 (enExample) |
| CA (1) | CA2850484C (enExample) |
| CY (1) | CY1122654T1 (enExample) |
| DK (2) | DK2760994T4 (enExample) |
| EA (1) | EA032699B1 (enExample) |
| ES (3) | ES2632444T5 (enExample) |
| IL (2) | IL231812B (enExample) |
| IN (1) | IN2014CN02518A (enExample) |
| MX (2) | MX359398B (enExample) |
| PT (2) | PT2760994T (enExample) |
| SG (2) | SG11201401077PA (enExample) |
| UA (1) | UA114796C2 (enExample) |
| WO (1) | WO2013049615A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| MX359398B (es) | 2011-09-30 | 2018-09-27 | Bluebird Bio Inc | Compuestos para transduccion viral mejorada. |
| WO2014022376A2 (en) | 2012-08-01 | 2014-02-06 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells |
| AU2013296611B2 (en) | 2012-08-01 | 2017-11-23 | United Therapeutics Corporation | Treatment of pulmonary arterial hypertension with mesenchymal stem cells |
| WO2014026110A2 (en) * | 2012-08-10 | 2014-02-13 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| AU2013352156B2 (en) | 2012-11-27 | 2018-12-06 | Children's Medical Center Corporation | Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction |
| EP2943069B1 (en) | 2013-01-09 | 2018-08-15 | United Therapeutics Corporation | Treatment of vasculopathy with prostacyclin and mesenchymal stem cells |
| JP6691048B2 (ja) * | 2013-10-24 | 2020-04-28 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
| JP2017511132A (ja) * | 2014-03-26 | 2017-04-20 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法 |
| SG10201809290SA (en) | 2014-04-25 | 2019-01-30 | Childrens Medical Ct Corp | Compositions and Methods to Treating Hemoglobinopathies |
| JP7288302B2 (ja) | 2015-05-08 | 2023-06-07 | ザ チルドレンズ メディカル センター コーポレーション | 胎児型ヘモグロビン再誘導のための、ｂｃｌ１１ａエンハンサー機能性領域を標的とする方法 |
| RU2630654C2 (ru) * | 2015-07-29 | 2017-09-11 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов |
| CN105062979A (zh) * | 2015-08-21 | 2015-11-18 | 昆明理工大学 | 一种培养戊型肝炎病毒的方法 |
| EP3413896B1 (en) * | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3014078A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3020330A1 (en) * | 2016-04-07 | 2017-10-12 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| IL262720B2 (en) | 2016-05-05 | 2024-06-01 | Liquidia Tech Inc | Dry powder treprostinil for the treatment of pulmonary hypertension |
| IL266175B2 (en) | 2016-10-24 | 2024-01-01 | United Therapeutics Corp | Enhancement of msc immunomodulatory properties by treprostinil |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| EP3600448A4 (en) * | 2017-03-29 | 2021-01-27 | Bluebird Bio, Inc. | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
| EP3681887B1 (en) * | 2017-09-15 | 2024-09-04 | The Medical College of Wisconsin, Inc. | Kidney-targeted epoxyeicosatrienoic acid (eet) analogs |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN109207427B (zh) * | 2018-09-17 | 2020-12-08 | 诺未科技（银川）有限公司 | 一种将人造血祖细胞转变为造血干细胞的方法 |
| CN110799641B (zh) * | 2018-04-13 | 2021-02-19 | 诺未科技（北京）有限公司 | 丁酸钠的用途及含有丁酸钠的培养体系 |
| US12239693B2 (en) | 2018-04-27 | 2025-03-04 | The Medical College Of Wisconsin, Inc. | Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders |
| EP3787600A4 (en) | 2018-05-02 | 2022-02-16 | The Children's Medical Center Corporation | ENHANCED BCL11A MICRORNAS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
| WO2020056400A1 (en) | 2018-09-14 | 2020-03-19 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| CN112805015A (zh) * | 2018-10-12 | 2021-05-14 | 生命技术公司 | 造血干细胞和造血祖细胞扩增系统 |
| CN113195003B (zh) * | 2018-11-30 | 2024-12-31 | 国立大学法人京都大学 | 使用溶液的药物递送系统 |
| US20220389448A1 (en) * | 2019-06-28 | 2022-12-08 | The Children's Hospital Of Philadelphia | Compositions and methods for treating anemia |
| AU2020365133A1 (en) * | 2019-10-16 | 2022-04-28 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| EP4158041A4 (en) * | 2020-06-02 | 2024-09-25 | Catalent Pharma Solutions, LLC | CELL LINES WITH MULTIPLE DOCKING ZONES FOR GENE INSERTION |
| CN115125270A (zh) * | 2021-03-22 | 2022-09-30 | 华东师范大学 | 一种α-珠蛋白过表达载体及其应用 |
| CN113106098B (zh) * | 2021-04-21 | 2022-04-01 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| CN113336833A (zh) * | 2021-06-04 | 2021-09-03 | 广州伯尼兹生物科技有限公司 | 一种高效分泌表达猪流行性腹泻病毒s1蛋白的生产方法 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| EP4569092A2 (en) | 2022-08-11 | 2025-06-18 | Fondazione Telethon ETS | Gene therapy of lysosomal storage disorders |
| WO2024079644A1 (en) | 2022-10-11 | 2024-04-18 | Fondazione Telethon Ets | 3d cell culture methods |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| IT202300011790A1 (it) | 2023-06-08 | 2024-12-08 | Fond Telethon Ets | Protocolli di manipolazione genica in cellule immunitarie |
| WO2025056970A1 (en) * | 2023-09-12 | 2025-03-20 | Virocell Biologics Ltd | Mammalian cell culture additives |
| IT202300022191A1 (it) | 2023-10-24 | 2025-04-24 | Fond Telethon Ets | Mezzi e metodi per la modifica genetica di uba1 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| EP4640830A1 (en) | 2024-04-23 | 2025-10-29 | Fondazione Telethon ETS | Means and methods for safe and efficient gene editing in cells |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| DE69312487T2 (de) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | Einrichtung zur transmucosalen wirkstoffabgabe |
| CA2165679A1 (en) | 1993-06-21 | 1995-01-05 | Tim M. Townes | Anti-sickling hemoglobin |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5869039A (en) | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
| JPH10509027A (ja) | 1994-09-19 | 1998-09-08 | マサチューセッツ インスティテュート オブ テクノロジー | 抗鎌状化β−グロビン蛋白質、組成物及び鎌状赤血球疾患を治療する方法 |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| AU720359B2 (en) * | 1995-09-29 | 2000-06-01 | Indiana University Research And Technology Corporation | Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| WO1998000541A2 (en) | 1996-07-03 | 1998-01-08 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of human disease |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| AU6339399A (en) | 1998-10-16 | 2000-05-08 | Novartis Ag | Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors |
| WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| US6670323B1 (en) | 1999-11-12 | 2003-12-30 | Baxter International, Inc. | Reduced side-effect hemoglobin compositions |
| ATE384704T1 (de) | 1999-12-17 | 2008-02-15 | Novartis Vaccines & Diagnostic | Pyrazin-basierte hemmer der glycogen-synthase- kinase 3 |
| IL141120A0 (en) | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| AU2002347563A1 (en) | 2001-12-06 | 2003-06-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| WO2003056019A1 (en) | 2001-12-24 | 2003-07-10 | Es Cell International Pte Ltd | Method of transducing es cells |
| US7250262B2 (en) | 2002-02-04 | 2007-07-31 | Bayerhealth Care Ag | Methods for identifying compounds which modulate hematopoiests |
| BR0313743A (pt) | 2002-08-23 | 2005-07-05 | Chiron Corp | Benzimidazol quinolinonas e usos destas |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP1581056B1 (en) | 2002-12-13 | 2010-07-21 | Genetix Pharmaceuticals Inc. | Therapeutic retroviral vectors for gene therapy |
| JP4865541B2 (ja) | 2003-04-08 | 2012-02-01 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法 |
| DE602004030105D1 (de) * | 2003-05-05 | 2010-12-30 | Virxsys Corp | Erhöhte transduktion mit abc-transportersubstratenhemmern |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| WO2006001463A1 (ja) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| AU2005299473B2 (en) | 2004-10-26 | 2012-06-28 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin EP4 agonists |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| WO2007041511A2 (en) | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| US8076315B2 (en) | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| CN101495623B (zh) | 2006-03-24 | 2013-09-11 | 儿童医疗中心有限公司 | 调节造血干细胞生长的方法 |
| ATE539170T1 (de) * | 2006-04-27 | 2012-01-15 | Univ Montreal | Abschätzung und verringerung des risikos von graft-versus-host-reaktion |
| WO2007148332A1 (en) | 2006-06-22 | 2007-12-27 | Yeda Resaerch And Development Co. Ltd | Catecholamine receptor modulation |
| EP2679221B1 (en) | 2006-10-20 | 2020-09-23 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| WO2008073748A1 (en) | 2006-12-08 | 2008-06-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| EP2131840B1 (en) | 2007-03-07 | 2018-10-17 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
| EP3031907B1 (en) * | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
| JP6037836B2 (ja) * | 2009-11-15 | 2016-12-07 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法 |
| MX359398B (es) | 2011-09-30 | 2018-09-27 | Bluebird Bio Inc | Compuestos para transduccion viral mejorada. |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| WO2014026110A2 (en) * | 2012-08-10 | 2014-02-13 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| JP6691048B2 (ja) * | 2013-10-24 | 2020-04-28 | オスペダーレ サン ラファエレ エス．アール．エル | 方法 |
| CN103937743B (zh) * | 2014-04-27 | 2017-12-01 | 浙江大学 | 一种利用三维诱导系统获得造血干细胞的方法 |
| EP3313420B1 (en) * | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| BR112018001232A2 (pt) * | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| EP3413896B1 (en) * | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3014078A1 (en) * | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| GB201706394D0 (en) * | 2017-04-21 | 2017-06-07 | Ospedale San Raffaele Srl | Gene Therapy |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
-
2012
- 2012-09-28 MX MX2014003923A patent/MX359398B/es active IP Right Grant
- 2012-09-28 WO PCT/US2012/057987 patent/WO2013049615A1/en not_active Ceased
- 2012-09-28 SG SG11201401077PA patent/SG11201401077PA/en unknown
- 2012-09-28 UA UAA201403867A patent/UA114796C2/uk unknown
- 2012-09-28 SG SG10201602423TA patent/SG10201602423TA/en unknown
- 2012-09-28 IN IN2518CHN2014 patent/IN2014CN02518A/en unknown
- 2012-09-28 ES ES12836507T patent/ES2632444T5/es active Active
- 2012-09-28 EP EP22161134.6A patent/EP4095236A1/en not_active Withdrawn
- 2012-09-28 PT PT128365079T patent/PT2760994T/pt unknown
- 2012-09-28 US US14/348,572 patent/US9988644B2/en active Active
- 2012-09-28 CN CN201280056851.7A patent/CN103958667A/zh active Pending
- 2012-09-28 CA CA2850484A patent/CA2850484C/en active Active
- 2012-09-28 CN CN201810168851.5A patent/CN108220246B/zh not_active Expired - Fee Related
- 2012-09-28 DK DK12836507.9T patent/DK2760994T4/da active
- 2012-09-28 BR BR112014007782-7A patent/BR112014007782B1/pt not_active IP Right Cessation
- 2012-09-28 PT PT171735673T patent/PT3269802T/pt unknown
- 2012-09-28 AU AU2012315699A patent/AU2012315699B2/en not_active Ceased
- 2012-09-28 ES ES19204363T patent/ES2913633T3/es active Active
- 2012-09-28 EP EP17173567.3A patent/EP3269802B1/en not_active Revoked
- 2012-09-28 ES ES17173567T patent/ES2769270T3/es active Active
- 2012-09-28 JP JP2014533413A patent/JP6285863B2/ja active Active
- 2012-09-28 EA EA201490627A patent/EA032699B1/ru unknown
- 2012-09-28 KR KR1020147011495A patent/KR102011532B1/ko not_active Expired - Fee Related
- 2012-09-28 EP EP12836507.9A patent/EP2760994B2/en active Active
- 2012-09-28 DK DK17173567.3T patent/DK3269802T3/da active
- 2012-09-28 EP EP19204363.6A patent/EP3656848B1/en active Active
-
2014
- 2014-03-30 IL IL231812A patent/IL231812B/en active IP Right Grant
- 2014-03-31 MX MX2018011791A patent/MX2018011791A/es unknown
-
2018
- 2018-02-02 JP JP2018017184A patent/JP6745826B2/ja not_active Expired - Fee Related
- 2018-06-04 US US15/997,643 patent/US10501759B2/en active Active
-
2019
- 2019-10-28 US US16/665,892 patent/US10907177B2/en active Active
-
2020
- 2020-01-22 CY CY20201100056T patent/CY1122654T1/el unknown
- 2020-12-17 US US17/125,930 patent/US11834668B2/en active Active
-
2021
- 2021-02-23 IL IL281045A patent/IL281045B/en unknown
-
2023
- 2023-11-30 US US18/525,721 patent/US20240229070A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530012A5 (enExample) | ||
| US11834668B2 (en) | Compounds for improved viral transduction | |
| WO2017139576A1 (en) | Vcn enhancer compositions and methods of using the same | |
| US20150216903A1 (en) | Compounds for improved viral transduction | |
| JP2020511991A5 (enExample) | ||
| AU2020365133A1 (en) | Compositions and methods for modifying eukaryotic cells |